Denong Wang, Ph.D., has long-term research interest in the carbohydrate moieties that are critical for self/non-self recognition and induction of antibody responses.

Wang and his team specialize in exploring the diversity of glycomes, to identify potential new treatments for cancer and viral diseases. Wang’s laboratory is part of an National Cancer Institute network launched in 2008 to conduct glycomics research. The team has established multiple platforms of carbohydrate microarrays and introduced these glycomics tools to explore the structural and antigenic diversities of the glycome. The main research focus of his lab is in the immunogenic sugar moieties. In the past few years, his group has contributed to the identification of immunologically potent glycan markers of SARS-CoV, Bacillus anthracis exosporium, and a number of human cancers.

Wang received his Ph.D. in immunology and glycobiology with the late Professor Elvin A. Kabat at Columbia University in 1993. After that, he entered the developing field of post-genomics research. Before joining SRI in 2010, he served as head of the Functional Genomics Division at Columbia University’s Genome Center from 1998 to 2003 and was director of Stanford University’s Tumor Glycome Laboratory from 2007 to 2010.